HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
Nature Review, recognized Apatinib’s potential as 3rd therapeutic agent for gastric cancer
HLB announced that Nature Review, the globally acknowledged scientific journal has reviewed Apatinib. According to the review titled, ‘Apatinib – 3rd therapy
for intractable gastric cancer treatment’, while there has not been globally recognized 3rd therapeutic agent for gastric cancer, Apatinib, which passed the clinical trial phase III in China, is now on the market, could be a global standard for 3rd therapy for gastric cancer, once its clinical trials in US and Europe proved to be good, it forecasts.
HLB official said, the positive evaluation on the acknowledged scientific journal is going to affect positive to the negotiations for the license, during the time of
preparing for global clinical trial phase III.
Also, HLB’s official added, “according to Deutsch Bank’s recent report on Hengrui Medicine Distribution Co., Ltd., the sales revenue this year, the 2nd year
on the market, will reach 3 times of its first year’s, that will be around RMB 780M.
This year, China is going to finish the clinical trial for gastric cancer’s 2nd therapeutic agent and clinical trial phase III of lung & hepatic cancer, which is
proving its potential as a new medicine for various applications”.
Sungchul Kim, who is leading the development of Apatinib in LSKB, a subsidiary of HLB’s, stated that, “the sales revenue in China has been the result of sales
as 3rd therapeutic agent for gastric cancer, thus it is greatly expected to increase the revenue once it secured the applications for 2nd therapeutic agent for lung, liver and gastric cancers. Including the Nature Review and other positive thesis about
Apatinib, and the rapid increase of sales in China will be a great help for the full scaled global clinical trial phase III this year and negotiations on the license”.
Jungmin Park, the CEO of HLB’s, said, “the Bio Division is going to make tangible results this year in 2016, which will be the first year of transforming HLB into
a Bio firm, We’ll add up various pipelines in addition to the BTK inhibitor which is already secured, planning that we could position ourselves with LSKB a center of specialized new medicine development company”.